Stock screenerAll disclosures →
EDGAR →
BEAM
Conviction 28HealthcareScan · Thu, Sep 24, 2026Beam Therapeutics Inc. (BEAM) closed at $24.68 (+1.27%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 42, RS Rating 36, -34.9% from its 52-week high, -9.1% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).
BEAM$24.68+1.27%
ResistanceSupportVol 14Insider sellVol MA14 2.39M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price24.68
Change+1.27%
Gap-2.01%
Rel volume2.01×
Avg volume2.04M
Avg $ vol52.86M
SMA 2026.37
SMA 5026.89
SMA 20028.56
Price vs 50-8.22%
Price vs 200-13.58%
MA stackbearish
50/200 crossdeath · 8d
Supertrenddown · 27.67
RSI (14)42
MACD hist-0.05
MACD cross—
Stoch %K / %D28 / 31
ADX (14)18
+DI / −DI20 / 28
RSI divergence—
MACD divergence—
ATR %6.27%
ADR %5.00%
52w high37.92
52w low20.60
From 52w high-34.92%
Above 52w low+19.81%
New 52w highNo
SqueezeOff
Bollinger width37.32%
%B0.33
Donchian pos24.66%
Donchian high30.82
Donchian low22.67
AVWAP (52w high)28.02
vs AVWAP high-11.91%
AVWAP (52w low)28.71
vs AVWAP low-14.05%
OBV trendFlat
Chaikin MF (20)0.06
Today vs 20d2.01×
Avg vol (14d)2.39M
Avg vol (20d)2.04M
Avg $ vol (20d)52.86M
Market cap2.55B
RS Rating36 / 99
RS 3m (vs SPY)-31.75%
RS 6m (vs SPY)-10.07%
RS line new highNo
Trend template2/8
Technical rank30.5
1 week+0.04%
1 month-20.46%
3 months-27.26%
6 months+6.75%
1 year+4.00%
YTD-9.06%
P/E-31.87
P/B2.39
P/S18.24
P/FCF-7.08
EPS-0.8100
Div yield—
ROE-7.49%
ROA-5.77%
Debt/Eq0.09
Current14.57
EV/EBITDA-6.72
Gross margin—
Net margin-57.24%
Rev growth120.01%
EPS growth78.77%
Price target52.30
Target upside111.91%
Analyst ratingBuy
Institutional118.54%
Ent. value2.43B
Revenue490K
Net income-122.68M
Gross profit—
Free cash flow-360.05M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out102.88M
Employees522
ListedThu, Feb 6, 2020
Free float79.74M
Float %78.3%
Short interest25.8M
Days to cover14.8d
Short volume70.7%
Squeeze score100 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$1.18 vs −$1.00
Last surprise-18.0% miss
Setup gradeD
Conviction28 / 100
Pattern quality—
Tech rank30.5 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance30.83
Support23.67
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Beam Therapeutics (BEAM) Stock Looks Fully Valued Despite In Vivo Gene Editing Growthsimplywall.st · Thu, Sep 24, 2026
- Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest GrowsYahoo Finance · Thu, Sep 24, 2026
- Beam Global (BEEM) stock price, news, quote and historyYahoo Finance Singapore · Wed, Sep 23, 2026
- A drone with conditional U.S. approval could be made in America if Beam Global buys its maker.stocktitan.net · Tue, Sep 22, 2026
- Tracking Cathie Wood: Adds BEAM and IONS, Reduces P and TXGMoomoo · Tue, Sep 22, 2026
- Beam Global Q2 revenue beats estimates; shares jump 26%scanx.trade · Mon, Sep 21, 2026
Congress activity
Disclosed STOCK Act trades in BEAM
No recent disclosed trades by Congress in BEAM. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in BEAM · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
FMR LLC 10% owner · Common Stock · 2026-06-26 | Sell | 251.49K | $8.9M | 2026-06-26 | 2026-06-29 |
FMR LLC 10% owner · Common Stock · 2026-06-25 | Sell | 33.37K | $1.2M | 2026-06-25 | 2026-06-29 |
Ciaramella Giuseppe President · Common Stock · 2026-06-17 | Exercise | 6.5K | $4K | 2026-06-17 | 2026-06-22 |
Ciaramella Giuseppe President · Common Stock · 2026-06-17 | Exercise | 29K | $30K | 2026-06-17 | 2026-06-22 |
Ciaramella Giuseppe President · Stock Option (Right to Buy) · 2026-06-17 | Exercise | 6.5K | — | 2026-06-17 | 2026-06-22 |
Ciaramella Giuseppe President · Stock Option (Right to Buy) · 2026-06-17 | Exercise | 29K | — | 2026-06-17 | 2026-06-22 |
Shaw Christi Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 19.68K | $0 | 2026-06-03 | 2026-06-05 |
Fishman Mark Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 19.68K | $0 | 2026-06-03 | 2026-06-05 |
MARAGANORE JOHN Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 19.68K | $0 | 2026-06-03 | 2026-06-05 |
COOPER GRAHAM K Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 19.68K | $0 | 2026-06-03 | 2026-06-05 |
SEC filings
EDGAR filings in BEAM · 8 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.